Literature DB >> 16185985

Photodynamic therapy with m-tetrahydroxyphenyl chlorin for high-grade dysplasia and early cancer in Barrett's columnar lined esophagus.

Laurence B Lovat1, Neil F Jamieson, Marco R Novelli, C Alexander Mosse, Chelliah Selvasekar, Gary D Mackenzie, Sally M Thorpe, Stephen G Bown.   

Abstract

BACKGROUND: Many patients with high-grade dysplasia and localized adenocarcinoma in Barrett's esophagus have localized disease but are either unfit for major surgery or decline esophagectomy. Photodynamic therapy with the powerful photosensitizer m-tetrahydroxyphenyl chlorin may be a nonsurgical therapeutic option.
METHODS: This is a pilot study to evaluate the efficacy and complications of m-tetrahydroxyphenyl chlorin photodynamic therapy. The design is a case series of 19 consecutive patients at a tertiary referral unit with a special interest in photodynamic therapy. The study included 7 patients with high-grade dysplasia and 12 with early esophageal cancer, who had refused or were unfit for esophagectomy. Three days after photosensitization with 0.15 mg/kg m-tetrahydroxyphenyl chlorin, red or green light was delivered endoscopically when using either a bare fiber or a diffuser device. Results were assessed by endoscopic surveillance.
RESULTS: By using red light via the diffuser, 4/6 patients with cancer and 3/4 with high-grade dysplasia were successfully treated with photodynamic therapy alone. When using the bare-tipped fiber, there was one procedure-related death and only 1/5 patients with cancers were successfully treated. Two others were downgraded to high-grade dysplasia. With green light delivered via a diffuser, 0/3 patients with high-grade dysplasia are in long-term remission. Two serious complications arose (including one death) from taking multiple biopsy specimens too soon after therapy. Two esophageal strictures occurred.
CONCLUSIONS: Photodynamic therapy with m-tetrahydroxyphenyl chlorin is, potentially, a valuable therapeutic option for localized esophageal neoplasia. Red light via a diffuser device appears to be the most effective light-delivery technique. Biopsy specimens should not be taken for at least 2 months after treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185985     DOI: 10.1016/j.gie.2005.04.043

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  7 in total

Review 1.  The role of photodynamic therapy (PDT) physics.

Authors:  Timothy C Zhu; Jarod C Finlay
Journal:  Med Phys       Date:  2008-07       Impact factor: 4.071

2.  Prevalence of adenocarcinoma at esophagectomy for Barrett's esophagus with high grade dysplasia.

Authors:  John Y Nasr; Robert E Schoen
Journal:  J Gastrointest Oncol       Date:  2011-03

3.  Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.

Authors:  Hector R Nava; Shyam S Allamaneni; Thomas J Dougherty; Michele T Cooper; Wei Tan; Gregory Wilding; Barbara W Henderson
Journal:  Lasers Surg Med       Date:  2011-09       Impact factor: 4.025

Review 4.  Endoscopic treatment of Barrett's esophagus: From metaplasia to intramucosal carcinoma.

Authors:  Jennifer Chennat; Irving Waxman
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

5.  How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus.

Authors:  Gary D Mackenzie; Neil F Jamieson; Marco R Novelli; C Alexander Mosse; Benjamin R Clark; Sally M Thorpe; Stephen G Bown; Laurence B Lovat
Journal:  Lasers Med Sci       Date:  2007-07-03       Impact factor: 3.161

Review 6.  Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy.

Authors:  Devidas Menon; Tania Stafinski; Heng Wu; Darren Lau; Clarence Wong
Journal:  BMC Gastroenterol       Date:  2010-09-27       Impact factor: 3.067

7.  Relationship between subcellular localisation of Foscan and caspase activation in photosensitised MCF-7 cells.

Authors:  S Marchal; A François; D Dumas; F Guillemin; L Bezdetnaya
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.